Literature DB >> 8639453

Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.

C Rintelen1, C Mannhalter, H Ireland, D A Lane, P Knöbl, K Lechner, I Pabinger.   

Abstract

In 29 patients (17 females) homozygous Arg 506 Gln mutation (FV Leiden) was identified. 25 had been investigated because of venous thromboembolism (VTE); four asymptomatic patients were found during family studies. The first VTE had occurred significantly earlier in females (median age [m] 26 years, range 17-49) than in males (m=38 years, range 21-82) (P=0.01). 12 females (80%) had taken oral contraceptives (OC, estrogen content 0.02-0.1 mg) for 6-150 months prior to thrombosis. Further triggering conditions in females were hormone replacement (n=1) and pregnancy (n=2). In 8/10 males the first VTE had occurred spontaneously--in two after surgery. The sites of VTE were deep vein thrombosis, pulmonary embolism, caval vein thrombosis and superficial thrombophlebitis. From our data we conclude that OC medication is the most important precipitating factor for VTE in females with homozygous FV Leiden.

Entities:  

Keywords:  Austria; Biology; Contraception; Contraceptive Methods; Developed Countries; Diseases; Embolism; Endocrine System; Estrogens; Europe; Examinations And Diagnoses; Family Planning; Genetics; Hormone Replacement Therapy; Hormones; Oral Contraceptives; Oral Contraceptives, Combined; Physiology; Research Report; Risk Factors; Screening; Thromboembolism; Thrombosis; Treatment; Vascular Diseases; Western Europe

Mesh:

Substances:

Year:  1996        PMID: 8639453     DOI: 10.1046/j.1365-2141.1996.5712013.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation.

Authors:  Ymir Saemundsson; Signý Vala Sveinsdottir; Henrik Svantesson; Peter J Svensson
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

2.  Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas.

Authors:  Johannes Thaler; Cihan Ay; Alexandra Kaider; Eva-Maria Reitter; Johanna Haselböck; Christine Mannhalter; Christoph Zielinski; Christine Marosi; Ingrid Pabinger
Journal:  Neuro Oncol       Date:  2014-07-01       Impact factor: 12.300

3.  Long term use of oral contraceptives without thrombosis in patients with FV Leiden polymorphism: a study of 37 patients (2 homozygous and 35 heterozygous).

Authors:  A Girolami; D Tormene; S Gavasso; C Bertolo; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.